| Bioactivity | Mazdutide (IBI-362; LY-3305677) is an glucagon-like peptide-1 (GLP-1R)/glucagon receptor GCGR co-agonist, and a long-acting synthetic oxyntomodulin analog. Mazdutide has safety and tolerability, and it can be used for research in obesity and type 2 diabetes (T2D)[1][2]. | ||||||
| Name | Mazdutide | ||||||
| CAS | 2259884-03-0 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light, under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen) |
||||||
| Reference | [1]. Chen T, et al. The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. J Med Chem. 2022 Mar 10;65(5):3685-3705. [2]. Jiang H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13(1):3613. |